Nifty, Sensex Achieve Amid COVID-19 Vaccine Hopes; Reliance Industries Leads Pack
BENGALURU (Reuters) - Indian shares were flat on Monday as prospects from the early roll-from COVID-19 vaccines were countered by fears in India inside the impact of further lockdowns, although Reliance Industries rose after winning regulatory approval for just about any $3.4 billion deal.
A higher U.S. health official mentioned on Sunday the initial coronavirus vaccines may be presented to healthcare workers while others recommended by mid-December, boosting Asian stock markets on Monday.
In India, the Nifty was up .04% at 12,864.10 by 0510 GMT. The Sensex eased .05% to 43,860.60.
Reliance Industries, India’s best public company, advanced a few ofPercent following a country’s competition watchdog approved its deal to buy Future Group’s retail assets.
Meanwhile, Maharashtra...